Journal article
Chemo-Immunotherapy in First Line Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Review and Meta-Analysis
Abstract
Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with early metastatic potential. The standard-of-care treatment has not changed in years. Recent studies report improved progression-free survival (PFS) and overall survival (OS) with combined ICI and chemotherapy in ES-SCLC. We conducted a systematic review and meta-analysis to assess the magnitude of survival benefits. We searched MEDLINE, EMBASE, and Cochrane between 1 …
Authors
Sathiyapalan A; Febbraro M; Pond GR; Ellis PM
Journal
Current Oncology, Vol. 29, No. 12, pp. 9046–9065
Publisher
MDPI
DOI
10.3390/curroncol29120709
ISSN
1198-0052